Dexrabeprazole

Dexrabeprazole

SCHEMBL22189141

COCCCOc1ccnc(C[S@@+]([O-])c2nc3ccccc3[nH]2)c1C.[NaH]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.60
CYP2C9 P11712 4/20 0.60
WDR5 P61964 4/20 0.60
LMNA P02545 4/20 0.60
ENGASE Q8NFI3 3/20 0.60
ALDH1A1 P00352 3/20 0.60
MAPT P10636 3/20 0.60
DDAH1 O94760 2/20 0.60
ADORA3 P0DMS8 2/20 0.60
HPGD P15428 2/20 0.60
TBXA2R P21731 2/20 0.60
NPY1R P25929 2/20 0.60
ADORA1 P30542 2/20 0.60
OPRM1 P35372 2/20 0.60
HTR3A P46098 2/20 0.60
FASN P49327 2/20 0.60
SARM1 Q6SZW1 2/20 0.60
ABCG2 Q9UNQ0 2/20 0.60
PDE4D Q08499 2/20 0.60
HTR1A P08908 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rabeprazole SCHEMBL2998947 1.00 KMT2A (0.60) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL2998946 1.00 KMT2A (0.60) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL491358 1.00 KMT2A (0.60) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL140495 1.00 KMT2A (0.60) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL27964348 0.99 KMT2A (0.59) KMT2ACYP2C9WDR5LMNAENGASE
Dexrabeprazole SCHEMBL30945135 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Dexrabeprazole SCHEMBL30019061 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Dexrabeprazole SCHEMBL4946138 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL29374701 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL23336 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078184-B2 Dexrabeprazole sodium compound and pharmaceutical composition thereof JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) 2021-08-03 US disclosed
CN-111423412-A Crystalline form of d-rabeprazole sodium anhydride 江苏海悦康医药科技有限公司 2020-07-17 CN disclosed
US-20200216414-A1 DEXRABEPRAZOLE SODIUM COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) 2020-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216414-A1 DEXRABEPRAZOLE SODIUM COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF CYP2C19, CYP2B6, CYP2D6 KMT2A 4196/4885CYP2C9 17/4885WDR5 3606/4885
US-11078184-B2 Dexrabeprazole sodium compound and pharmaceutical composition thereof CYP2C19, CYP2B6, CYP2D6 KMT2A 4196/4885CYP2C9 17/4885WDR5 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.